1180 related articles for article (PubMed ID: 18997760)
1. Enforcing pharmaceutical and biotech patent rights in China.
Zhang YP; Deng MM
Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
[No Abstract] [Full Text] [Related]
2. "Obvious to try": a proper patentability standard in the pharmaceutical arts?
Trask AV
Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581
[No Abstract] [Full Text] [Related]
3. Science and the law. Working through the patent problem.
Walsh JP; Cohen WM; Arora A
Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
[No Abstract] [Full Text] [Related]
4. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
5. A guide to drug discovery. Protecting your inventions: the patent system.
Webber PM
Nat Rev Drug Discov; 2003 Oct; 2(10):823-30. PubMed ID: 14526385
[TBL] [Abstract][Full Text] [Related]
6. Intellectual property. Fixing the legal framework for pharmaceutical research.
Knowles SM
Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
[No Abstract] [Full Text] [Related]
7. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
Westerlund L
Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
[No Abstract] [Full Text] [Related]
8. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
9. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
Teitelbaum R; Cohen M
Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
[No Abstract] [Full Text] [Related]
10. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech.
Garber K
Science; 2006 May; 312(5775):827. PubMed ID: 16690824
[No Abstract] [Full Text] [Related]
11. China tightens IP protection, but concerns linger.
Jia H
Nat Biotechnol; 2009 Sep; 27(9):787-8. PubMed ID: 19741619
[No Abstract] [Full Text] [Related]
12. International patent law-boon or bane of biotech?
Basu P
Nat Biotechnol; 2005 Jan; 23(1):13-5. PubMed ID: 15637604
[No Abstract] [Full Text] [Related]
13. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
14. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
15. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
Furrow ME
Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
[No Abstract] [Full Text] [Related]
16. US courts narrow patent exemptions.
Fox JL
Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
[No Abstract] [Full Text] [Related]
17. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
[TBL] [Abstract][Full Text] [Related]
18. Patent watch: Progress in three key patent disputes in 2009.
Nat Rev Drug Discov; 2010 Jan; 9(1):12-3. PubMed ID: 20050395
[No Abstract] [Full Text] [Related]
19. Proposed changes to patent code loom over biotech industry.
Coombs A
Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010
[No Abstract] [Full Text] [Related]
20. Auctioning the cure.
Willyard C
Nat Med; 2011 May; 17(5):528-30. PubMed ID: 21546960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
